
<!DOCTYPE html>
<html>
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>TTP</title>
    <style>
        body { max-width: 800px; margin: 40px auto; padding: 0 20px; font-family: -apple-system, system-ui, sans-serif; }
        pre { overflow-x: auto; }
        table { border-collapse: collapse; width: 100%; }
        th, td { border: 1px solid #ddd; padding: 8px; text-align: left; }
        details { margin: 20px 0; padding: 10px; background: #f5f5f5; border-radius: 4px; }
    </style>
</head>
<body>
    <h1>Complex TTP Management with Neurological Deterioration</h1>
<h2>Question</h2>
<p>A 35-year-old woman presents with:</p>
<ul>
<li>New onset seizures</li>
<li>Platelets: 12,000/µL (12 x 10⁹/L)</li>
<li>Hemoglobin: 7.2 g/dL (72 g/L)</li>
<li>Schistocytes on smear</li>
<li>LDH: 1200 U/L (20× ULN)</li>
<li>Creatinine: 2.1 mg/dL (185.6 µmol/L)</li>
<li>ADAMTS13 activity pending</li>
</ul>
<p>After starting plasma exchange, she develops:</p>
<ul>
<li>Status epilepticus</li>
<li>Respiratory failure requiring intubation</li>
<li>Cardiogenic shock (Troponin-I: 15 ng/mL)</li>
<li>DIC (fibrinogen 80 mg/dL)</li>
<li>Central line-associated DVT</li>
</ul>
<p>Which management strategy offers the best survival benefit?</p>
<h2>Options</h2>
<table>
<thead>
<tr>
<th>Option</th>
<th>Description</th>
</tr>
</thead>
<tbody><tr>
<td>A)</td>
<td>Double-volume plasmapheresis + rituximab + steroids + ECMO + continue anticoagulation</td>
</tr>
<tr>
<td>B)</td>
<td>Single-volume plasmapheresis + caplacizumab + hold anticoagulation</td>
</tr>
<tr>
<td>C)</td>
<td>Switch to hemodialysis + IVIG + platelet transfusion</td>
</tr>
<tr>
<td>D)</td>
<td>Fresh frozen plasma infusion + cyclophosphamide + IVC filter</td>
</tr>
<tr>
<td>E)</td>
<td>Therapeutic plasma exchange + splenectomy + antiepileptics</td>
</tr>
</tbody></table>
<details>
<summary>View Answer</summary>

<h2>Correct Answer</h2>
<p>A</p>
<h2>Explanation</h2>
<p>This is a catastrophic TTP case with multiple life-threatening complications:</p>
<ol>
<li><p>Disease Severity Assessment:</p>
<ul>
<li>Severe thrombocytopenia with end-organ damage</li>
<li>Neurological deterioration</li>
<li>Cardiac involvement</li>
<li>Respiratory failure</li>
<li>DIC complication</li>
<li>Thrombotic complications</li>
</ul>
</li>
<li><p>Management Rationale:</p>
<ul>
<li>Double-volume plasmapheresis:<ul>
<li>More rapid ADAMTS13 replacement</li>
<li>Better clearance of autoantibodies</li>
<li>Indicated in neurological deterioration</li>
</ul>
</li>
<li>Rituximab:<ul>
<li>Early administration improves outcomes</li>
<li>Reduces relapse risk</li>
<li>Addresses autoimmune component</li>
</ul>
</li>
<li>ECMO support:<ul>
<li>Manages cardiogenic shock</li>
<li>Provides respiratory support</li>
<li>Allows time for treatment response</li>
</ul>
</li>
</ul>
</li>
<li><p>Critical Considerations:</p>
<ul>
<li>Anticoagulation must continue despite bleeding risk:<ul>
<li>Catastrophic microthrombi formation</li>
<li>Central line maintenance</li>
<li>DVT presence</li>
</ul>
</li>
<li>Platelet transfusion contraindicated unless life-threatening bleeding</li>
<li>IVC filter contraindicated (increases thrombosis risk)</li>
<li>Splenectomy outdated, high mortality risk</li>
</ul>
</li>
<li><p>Expected Outcomes:</p>
<ul>
<li>Mortality &gt;90% without aggressive intervention</li>
<li>~70% survival with optimal management</li>
<li>Neurological recovery possible with prompt treatment</li>
</ul>
</li>
</ol>
<h2>References</h2>
<ul>
<li>Blood 2020: &quot;Management of TTP in the ICU Setting&quot;</li>
<li>NEJM 2019: &quot;Caplacizumab in TTP&quot;</li>
<li>Lancet Haematol 2021: &quot;Critical Care Management of TTP&quot;</li>
<li>J Thromb Haemost 2020: &quot;Guidelines for TTP Treatment&quot;</details></li>
</ul>

</body>
</html>